We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
동유럽임상시험수탁기관인OCT 클리니컬(OCT Clinical)은신흥바이오테크기업을위한종양학임상연구를위한OCT 종양학솔루션을출시하고종합서비스를확장한다고발표했다.
신흥바이오테크회사를포함한제약회사들은연구개발비용이점진적으로증가해지난몇년동안수익을앞지르면서임상연구에있어비용대비효율적인솔루션을찾기시작했고OCT는이에응하기위해새로운종합서비스를출시한것이다.
OCT 클리니컬은종양학약물개발프로세스의파트너를찾는스폰서에게더나은서비스를제공하기위해포괄적이면서실현가능한서비스를제공한다. 아울러 10개국에걸친300개의우수종양학클리닉과의독점파트너쉽, 최대4배까지빠른모집, 시험에타당한환자에대한접근성및난소암, 비소세포폐암, 두경부암및고형종양을포함한45개이상의적응증에대한전문지식을보유하고있다.
OCT의임상개발솔루션에는데이터수집및평가에있어특정암유형과관련된미묘한차이까지이해하는의료전문가및생물통계학자의프로토콜개발컨설팅이포함된다. 헌신적이며숙련된프로젝트팀은종양학에중점을둔의료전문가와경험이많은연구원들로구성되어있다.
면역종양학연구에는추가적인지연을야기시킬수있는, 다른연구와는완전히다른복잡성이있다. 이에OCT는표적치료제개발에성공하기위해서는혁신적인방법을사용하여올바른치료법을신속하게식별하고이를올바른환자에게전달해야한다. OCT 클리니컬은2011년부터면역치료연구를성공적으로진행하고있다.
OCT의임상프로젝트관리자인개티스클라우칸스(Gatis Klaucans)는“우리는전세계의많은스폰서들에게종양학임상연구에있어신뢰할수있는파트너로서오랜역사를가지고있다.” 며, “OCT 종양학을설계하고출시한것은약물개발에있어스폰서의요구를충족시키고시험관리를단순화하면서양질의임상데이터전달을최적화하기위한전략적움직임이다.” 고밝혔다.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
